Learn More >

Ministry Status: Activation Status

Patient Evidence Submissions

Drug Review Schedule

The Ontario Public Drug Program is currently accepting submissions of patient evidence on the following drug products which will undergo review by the Committee to Evaluate Drugs within the next 12 months.

Drug products on this list include new chemical entities, new combination products and existing drug products with a new indication recently approved by Health Canada. At this time, drug products that are line extensions (such as additional strengths and new dosage forms) and drug products that are undergoing reconsideration (second review, etc.) will not be considered for patient submissions. The Ministry will re-evaluate this once additional experience on the process is gained.

For drug products accepted for Rapid Review process, best efforts will be made to provide maximal time for patient submissions. However, in view of the intent of Rapid Review, the review of a drug product accepted for Rapid Review will not be held if only to include presentation of patient submissions.

Registered patient groups are invited to provide patient evidence on any of the drugs listed below.

All submissions must be received by 5:00pm of the deadline date.

 

Generic Name Brand Name Manufacturer Indication / Type of Review Deadline for Patient Submissions
Letermovir Prevymis Merck Canada Inc. Cytomegalovirus infection, prophylaxis (CDR) May 23, 2018
Trifluridine/tipiracil Lonsurf Taiho Pharma Canada Inc. Colorectal cancer, metastatic (pCODR) May 23, 2018
Exemestane Aromasin, generics Pfizer Canada Inc., others (Cancer Care Ontario submission) Breast cancer, hormone receptor-positive, early stage, in pre-/peri-menopausal women who have received or are receiving chemotherapy (as adjuvant therapy with ovarian suppression [leuprolide acetate, goserelin acetate, or triptorelin pamoate]) May 2, 2018
Goserelin acetate Zoladex AstraZeneca Canada Inc. (Cancer Care Ontario submission) Request for funding under the New Drug Funding Program for: Breast cancer, hormone receptor-positive, early stage, in pre-/peri-menopausal women who have received or are receiving chemotherapy (as adjuvant therapy with exemestane or tamoxifen) May 2, 2018
Leuprolide acetate Eligard / Lupron Abbvie Corporation / Sanofi Aventis Canada Inc. (Cancer Care Ontario submission) Request for funding under the New Drug Funding Program for: Breast cancer, hormone receptor-positive, early stage, in pre-/peri-menopausal women who have received or are receiving chemotherapy (as adjuvant therapy with exemestane or tamoxifen) May 2, 2018
Triptorelin pamoate Trelstar Actavis Specialty Pharmaceuticals Co. (Cancer Care Ontario submission) Request for funding under the New Drug Funding Program for: Breast cancer, hormone receptor-positive, early stage, in pre-/peri-menopausal women who have received or are receiving chemotherapy (as adjuvant therapy with exemestane or tamoxifen) May 2, 2018
Inotuzumab ozogamicin Besponsa Pfizer Canada Inc. Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) (pCODR) April 25, 2018
Avelumab Bavencio EMD Serono-Pfizer Alliance Merkel cell carcinoma, metastatic (pCODR) March 21, 2018
Nivolumab Opdivo Bristol-Myers Squibb Canada Hodgkin lymphoma (after failure of autologous stem cell transplant) (pCODR) March 21, 2018
Tenofovir alafenamide Vemlidy Gilead Sciences Canada, Inc. Hepatitis B, chronic (CDR) March 21, 2018
Methylphenidate hydrochloride Foquest Purdue Pharma Inc. Attention deficit hyperactivity disorder (ADHD) in adults March 1, 2018
Brentuximab vedotin Adcetris Seattle Genetics, Inc. Hodgkin lymphoma (after autologous stem cell transplant and at high risk of relapse or progression) (pCODR) February 21, 2018
Buprenorphine/naloxone Suboxone Indivior Canada Ltd. Substitution treatment for opioid dependence (request for funding of new tablet strengths) February 21, 2018
Guselkumab Tremfya Janssen Inc. Psoriasis, plaque, moderate to severe (CDR) February 21, 2018
Tocilizumab Actemra Hoffmann-La Roche Limited Giant cell arteritis (CDR) February 21, 2018
Regorafenib Stivarga Bayer Inc. Hepatocellular carcinoma, unresectable (after treatment with sorafenib) (pCODR) February 21, 2018

See also:

Image:Pdf icon.gif To view PDF format files, you need to have Adobe Acrobat® Reader installed on your computer.
You can download this free software from the Adobe Web site.

For More Information

Call ServiceOntario, Infoline at:
1-866-532-3161 (Toll-free)
In Toronto, (416) 314-5518
TTY 1-800-387-5559.
In Toronto, TTY 416-327-4282
Hours of operation : Monday to Friday, 8:30am - 5:00pm